Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04613362
Other study ID # IRP 20-002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2020
Est. completion date June 30, 2023

Study information

Verified date August 2023
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this pilot study is to evaluate a bundle of implementation strategies at three Veteran Affairs Medical Centers (VAMCs) to facilitate the referral and adoption of a telehealth based, cognitive behavioral therapy program delivered by Health Psychologists for Veterans with chronic migraine to inform a future fully-powered hybrid type 2 effectiveness-implementation design. Veteran patients will be randomized to either the telehealth delivered CBT or usual care. Headache symptoms and severity will be reported using a VA text messaging application.


Description:

With VHA's infrastructure dedicated to efficient telehealth delivery into patient homes, the delivery of a behavioral intervention for chronic migraine, CM, via the telehealth platform is primed to address barriers of in-person care delivery and holds considerable promise to reach and improve Veteran headache-related quality of life. Therefore, the goal is to evaluate an adapted bundle of EB implementation strategies to increase adoption of a Telemedicine-based Cognitive Behavioral Therapy (CBT) program (TENACITY) for CM in 2 VA HCoEs (VA Connecticut Healthcare System [VACHS], a large, multi-disciplinary HCoE, and Birmingham VA Medical Center [BVAMC], a smaller VA Headache Consortium Center. The HCoEs are charged with improving headache care throughout the VA, not just within an individual VAMC. As part of this study, a non-HCoE will also participate, providing an opportunity for the TENACITY study to extend this virtual specialty headache care to Veterans without headache specialty care. Dallas VA Medical Center, also known as the North Texas Health Care System [NTHCS] will participate as a third site. The investigators will determine whether TENACITY can be efficiently delivered through the vehicle of telehealth by conducting a pilot randomly controlled trial (RCT) comparing a) TENACITY to b) behavioral treatment as usual (TAU; i.e., behavioral usual care). The investigators will recruit Veterans diagnosed with chronic migraine during the one-year recruitment period across the 3 VAMCs. The investigators will randomize eligible Veterans to participate either in the TENACITY intervention (n=50) or treatment as usual (n=50). The specific aims are threefold: Aim 1: To develop a bundle of evidence-based practice (EBP) implementation strategies to engage 3 VA Medical Centers [2 Headache Centers of Excellence HCoEs and 1 general neurology service] and facilitate their local adaptation and implementation of Cognitive Behavioral Therapy (CBT) (TENACITY) through the vehicle of telehealth services. Hypothesis 1a. HCoE clinical providers will report high acceptability, appropriateness and fidelity of TENACITY at 3 months and maintenance at 6 months. Hypothesis 1b. TENACITY reach, adoption, and implementation will vary by HCoE local context as evaluated by the Consolidated Framework for Implementation Research (CFIR) inner settings. Aim 2. To conduct a pilot RCT and determine the preliminary efficacy and feasibility of TENACITY compared to TAU across 3 VA sites. Hypothesis 2: Veterans receiving TENACITY will experience a statistically significant reduction in routine clinical headache metrics: headache frequency [headache days per month] (primary outcome), headache-related impairment and psychological symptoms (secondary outcomes) compared to usual care at 3 and 6 months. Aim 3: The investigators will conduct exploratory cost analysis of TENACITY from the Veteran's perspective, using inputs from the pilot RCT, and a two-year budget impact analysis from the VHA's perspective, incorporating the costs of implementation as well as direct costs (and cost-savings,) of providing the TENACITY intervention over all HCoEs to VHA. Hypothesis 3: TENACITY will be cost-effective and provide value to Veterans and VHA.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date June 30, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Veteran patients eligible to participate must have: - A chronic migraine headache ICD-10 diagnosis; - Completion of at least 28 headache diary days; - A confirmed frequency of at least 8 headache days per month; - A primary complaint of headache Exclusion Criteria: Veteran patients not eligible to participate include: - Non-Veterans; - Veteran patients without a CM headache ICD-10 diagnosis; - Veteran patients whose primary pain complaint is not headache; - Veteran patients who have received greater than or equal to 90 days of opioid therapy for chronic low back pain from the date of chart screening; - Veteran patients who do not speak English; - Veteran patients who have a current diagnosis of severe cognitive impairment indicated by clinical provider, medical chart, or Short Portable Mental Status Questionnaire (SPMSQ); - Veteran patients who have Post Traumatic headache; - Veteran patients who have a diagnosis of cluster headache, other primary headache, post-whiplash headache, secondary headache, or trigeminal autonomic cephalalgia. - Any patients currently suffering from a disabling psychiatric illness (as noted by clinician); - Veteran patients who self-report Traumatic Brain Injury less than or equal to 1 year before diagnosis of Chronic Migraine, or worsening of Chronic Migraine. - Veteran patients who relate daily suicidal ideation within the last 2 weeks as indicated by the PHQ-9 with an answer of "3" to question nine; - Veteran patients who have severe depression, as indicated by PHQ-9 score greater than or equal to 20; - Veteran patients who are deemed by clinicians who are unable to participate in this trial; - Patients who are terminally ill (life expectancy of <12 months as noted by clinician); - Patients who are homeless or live in long-term care, nursing home, rehabilitation, or domiciliary services, etc. - Veteran patients who decline to or cannot use the Annie App; - Veteran patients who decline to or cannot use My HealtheVet secure messaging - Veteran patients who have been treated by a HCoE clinical health psychologist in the last two years

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
TENACITY Telehealth Cognitive Behavioral Therapy for Migraine
Clinical health psychology therapy delivered via telehealth
Behavioral Usual Care
Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.

Locations

Country Name City State
United States Birmingham VA Medical Center, Birmingham, AL Birmingham Alabama
United States VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX Dallas Texas
United States Richard L. Roudebush VA Medical Center, Indianapolis, IN Indianapolis Indiana
United States VA Connecticut Healthcare System West Haven Campus, West Haven, CT West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (2)

Goldman RE, Damush TM, Kuruvilla DE, Lindsey H, Baird S, Riley S, Burrone Bs L, Grinberg AS, Seng EK, Fenton BT, Sico JJ. Essential components of care in a multidisciplinary headache center: Perspectives from headache neurology specialists. Headache. 2022 — View Citation

Seng EK, Fenton BT, Wang K, Lipton RB, Ney J, Damush T, Grinberg AS, Skanderson M, Sico JJ. Frequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine: A VA Nationwide Cohort Study. Neurology. 2022 Sep 13;99(18):e1979-92 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Migraine-Specific Quality of Life Questionnaire (MSQ) Self-reported migraine related functioning 3 and 6 months
Other Migraine Disability Assessment (MIDAS) Self-reported disability due to migraines 3 and 6 months
Other Headache-specific Pain Catastrophizing Scale (HPCS) Self-reported headache pain 3 and 6 months
Other Headache Management Self-Efficacy Scale (HMSE) Self-reported confidence to manage headaches 3 and 6 months
Other Personal Health Inventory short form Self-reported health 3 and 6 months
Other PCL-5 (PTSD Checklist for DSM-5) Self-reported PTSD symptoms 3 and 6 months
Other Patient Health Questionnaire - PHQ-9 Self-reported depressive symptoms 3 and 6 months
Other Generalized Anxiety Disorder (GAD-7) Self-reported anxiety symptoms 3 and 6 months
Other Veterans RAND 12 (VR-12) Self-reported functioning and well-being 3 and 6 months
Other Insomnia Severity Index (ISI) Self-reported sleep disruptions 3 and 6 months
Primary Number of Headache Days in the 30 days Prior to 3-Month Mark Daily self-reported migraine headaches using a VA text message protocol 30 days prior to 3-Month Outcomes after Baseline
Secondary Implementation fidelity to the core functions of TENACITY Degree to which the core components of TENACITY are delivered as intended 3 months
Secondary Budget Impact Analysis Costs associated with program implementation 2 years
See also
  Status Clinical Trial Phase
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Completed NCT01211145 - Zomig - Treatment of Acute Migraine Headache in Adolescents Phase 4
Completed NCT00530517 - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Phase 2
Completed NCT00898677 - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) Phase 3
Completed NCT03971071 - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache Phase 4
Withdrawn NCT02706015 - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks Phase 3
Terminated NCT02375789 - Intranasal Cooling for Symptomatic Relief of Migraine N/A
Completed NCT02518464 - Ticagrelor Therapy for RefrACTORy Migraine Study Phase 4
Terminated NCT00391755 - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Phase 4
Completed NCT03401346 - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults Phase 1
Completed NCT05085483 - Ketone for Migraine Prevention N/A
Completed NCT01604785 - Low-dose Propofol for Pediatric Migraine Phase 2/Phase 3
Terminated NCT00804973 - Study in Participants With Acute Migraines Headaches Phase 2
Completed NCT03341689 - Psilocybin for the Treatment of Migraine Headache Phase 1
Completed NCT01630044 - Neurostimulation Device for Treatment of Migraine Headache N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT00203255 - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache N/A
Recruiting NCT06046508 - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
Active, not recruiting NCT04584762 - Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine N/A